Beximco Pharmaceuticals Ltd Notice of Preliminary Results and AGM (6276U)

TIDMBXP

RNS Number : 6276U

Beximco Pharmaceuticals Ltd

26 October 2017

BEXIMCO PHARMACEUTICALS LTD.

26 October 2017

Notification of Preliminary Results and Annual General Meeting

Beximco Pharmaceuticals Ltd. ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 25(th) October, 2017 has decided the following:

 
 1.   To recommend the approval      :   The Audited Financial 
       of the Financial Statements        Statements for the 
       for the year ended 30              year ended 30 June 2017 
       June 2017                          have been 
                                          approved. The full accounts 
                                          are expected 
                                          to be announced by 6 
                                          November 2017 
---  -----------------------------      ----------------------------- 
 2.   Date & Time of 41(st)          :   23 December 2017 at 10.00 
       AGM of the Company for             am 
       the year ended 30 June 
       2017 
---  -----------------------------      ----------------------------- 
 3.   Venue of AGM                   :   Beximco Industrial Park, 
                                          Sarabo, Kashimpur, Gazipur, 
                                          Bangladesh 
---  -----------------------------      ----------------------------- 
 4.   Proposed Dividend for          :   12.5% Cash Dividend (i.e. 
       the year ended 30 June             Tk.1.25 per share) 
       2017 
---  -----------------------------      ----------------------------- 
 5.   Record date                    :   15 November 2017 
---  -----------------------------      ----------------------------- 
 6.   Net Asset Value as at          :   Taka 25,072,425,900 
       30 June 2017 
---  -----------------------------      ----------------------------- 
 7.   Net Asset Value per            :   Taka 61.82 
       Share as at 30 June 
       2017 
---  -----------------------------      ----------------------------- 
 8.   Earnings per share (EPS)       :   Taka 5.49 
       for the year ended 30 
       June 2017 
---  -----------------------------      ----------------------------- 
 9.   Net Operating Cash Flow        :   Taka 6.49 
       per share for the year 
       ended 30 June 2017 
---  -----------------------------      ----------------------------- 
 

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: [phone], ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; [phone], [phone], Ext 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Sean Wyndham-Quin

Tel: [phone] / 3555

Northland Capital Partners Limited (Broker)

Gerry Beaney / Tom Price

Tel: [phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORZELFLDBFZFBX

(END) Dow Jones Newswires

October 26, 2017 02:00 ET (06:00 GMT)